IntrinsicIntrinsic
← All summaries

CytomX Therapeutics, Inc.

CTMX
Financials & Chart →

Business Summary

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company specializing in conditionally activated, masked biologics through its proprietary PROBODY technology platform. The company's core business model revolves around the discovery, development, and potential commercialization of these therapeutics, primarily generating revenue through non-refundable license payments, milestone payments, and reimbursements for research and development expenses under collaboration agreements. The PROBODY platform leverages tumor-associated enzymes (proteases) to remove a peptide mask from biologic therapeutics, allowing selective binding to targets in the tumor microenvironment and minimizing toxicity in healthy tissues. This multi-modality platform is applied to antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and cytokines, with the goal of optimizing the therapeutic index for cancer treatment. The company's primary customer segments are major biopharmaceutical companies with whom they form strategic alliances to extend technology reach and secure non-dilutive capital .

The company's most advanced clinical-stage program is Varsetatug Masetecan (Varseta-M), an investigational, conditionally activated ADC targeting epithelial cell adhesion molecule (EpCAM). Varseta-M is initially focused on late-line metastatic colorectal cancer (CRC), a disease with over 1.9 million cases diagnosed annually worldwide and a 5-year survival rate of only 13% . The ADC is armed with a topoisomerase-1 inhibitor payload, licensed from AbbVie (formerly ImmunoGen), designed for bystander killing of neighboring tumor cells. EpCAM is a validated cancer target, but previous systemic targeting efforts were limited by dose-limiting toxicities, which Varseta-M aims to overcome through its masking strategy. The company envisions Varseta-M becoming a core component of CRC treatment in earlier lines of therapy and a pan-tumor therapy for other EpCAM-expressing tumors like gastric, pancreatic, and ovarian cancers .

Another key product in the pipeline is CX-801, an investigational, dually-masked, conditionally activated version of interferon alpha-2b (IFNα2b), currently in Phase 1 clinical trial. CX-801 is designed to be inactive in the periphery and preferentially active in the tumor microenvironment, leveraging IFNα2b's dual mechanism of directly killing cancer cells and increasing antigen presentation. The program is initially focused on late-line melanoma, aiming to re-activate the immune system and improve patient outcomes in combination with PD-1 inhibition. The ultimate vision for CX-801 is to become a cornerstone of combination immunotherapy for a wide range of tumor types, including those refractory to prior checkpoint inhibition .

In addition to clinical programs, CytomX has preclinical PROBODY programs, particularly in T-cell engaging bispecific therapies (TCEs) with partners like Bristol Myers Squibb and Regeneron. An example is CX-908, a dually-masked PROBODY TCE targeting CDH3 and CD3, which demonstrated potent tumor regressions and a 100-fold improvement in tolerability in preclinical models. The company also has collaborations with ModernaTX, Inc. for mRNA-based conditionally-activated investigational therapies .

For the fiscal year ended December 31, 2025, total revenue was $76.201 million , a decrease of $61.902 million from $138.103 million in 2024. Research and development expenses decreased by $14.654 million to $68.728 million in 2025 from $83.382 million in 2024. General and administrative expenses remained flat at $29.837 million in 2025 compared to $29.726 million in 2024. The company reported an accumulated deficit of $711.9 million as of December 31, 2025, compared to $691.6 million as of December 31, 2024. Cash, cash equivalents, and short-term investments stood at $137.1 million as of December 31, 2025, up from $100.6 million in 2024. Net cash used in operating activities was $75.587 million in 2025, an improvement from $86.231 million in 2024. Net cash provided by financing activities was $110.446 million in 2025, primarily from equity issuances, compared to $7.522 million in 2024.

The decrease in revenue in 2025 compared to 2024 was primarily due to the completion of performance obligations under the Bristol Myers Squibb Agreement, a decrease in revenue under the Astellas Agreement due to increased projected hours to completion and lower preclinical milestone payments, a decrease under the Regeneron Agreement due to focus on the lead preclinical program, and a significant decrease under the Moderna Agreement due to a pause in programs driven by budget considerations. This was partially offset by the recognition of all remaining deferred revenue under the Amgen Agreement following the termination of its license to the EGFR Product . The reduction in research and development expenses was mainly due to reduced general R&D expenses from the January 2025 restructuring and a reduction in CX-904 spend due to program deprioritization, partially offset by higher Varseta-M manufacturing and clinical spend and $1.7 million in one-time restructuring expenses .

During 2025, CytomX announced a restructuring plan on January 6, 2025, which resulted in a reduction of approximately 40% of its workforce, primarily research and general and administrative staff, to streamline the organization and prioritize Varseta-M, CX-801, and research collaborations. This restructuring was substantially completed in the first quarter of 2025, incurring total charges of approximately $2.8 million , with $1.7 million in research and development expenses and $1.1 million in general and administrative expenses. In May 2025, the company completed an underwritten public offering of 76,923,076 shares of common stock at $1.30 per share , generating net proceeds of approximately $93.4 million . The company also sold 4,872,861 shares under its ATM offering in 2025 for net proceeds of approximately $16.3 million .

Business Outlook

CytomX Therapeutics expects its existing capital resources to be sufficient to fund operations into the second quarter of 2027 . However, the company will need to raise additional capital to fund future operations, with no assurance that such efforts will be successful or on favorable terms . The company's future capital requirements and the period for which existing resources will support operations may vary significantly based on factors such as the progress of preclinical and clinical development, clinical trial results, operating costs, and the timing and amount of payments under collaboration agreements .

A major growth area is the advancement of Varseta-M towards late-phase development, with a top priority to align with the FDA in 2026 on a potential registrational study for Varseta-M monotherapy in advanced late-line CRC . The company also initiated a Phase 1 study of Varseta-M in combination with bevacizumab in the first quarter of 2026, with initial data expected by the first half of 2027 . Furthermore, a Phase 1b/2 study of Varseta-M in combination with bevacizumab and chemotherapy is expected to start by the end of 2026 . Beyond CRC, CytomX plans to explore the pan-tumor potential of Varseta-M by initiating Phase 1 expansion cohorts in one or more additional EpCAM-positive solid tumor indications in the second half of 2026 .

Another significant growth vector is the advancement of CX-801, a masked version of interferon alpha-2b, in Phase 1 development. The company's priority for CX-801 is to report Phase 1 clinical data from the CX-801 and KEYTRUDA combination dose escalation portion of the study by the end of 2026 . The ultimate vision is to position CX-801 as a cornerstone of combination immunotherapy for a wide range of tumor types, including those refractory to prior checkpoint inhibition or historically insensitive to immunotherapy .

Operationally, the company's research and development expenses are expected to be primarily focused on Varseta-M and CX-801 in 2026 . The 2025 Restructuring Plan, which reduced the workforce by approximately 40% , was implemented to streamline the organization and preserve capital for these high-priority clinical trials and collaboration partner activities . The company expects to continue to rely on third-party contract manufacturers for its clinical trial and preclinical study product supplies, acknowledging the sole-source nature of many of these suppliers and the potential for supply chain disruptions .

Regarding capital allocation, the company's monthly spending levels vary based on ongoing clinical trials, new and ongoing research and development, and other corporate activities . As of December 31, 2025, approximately $39.4 million remained available under the ATM program for future equity issuances . The company currently intends to retain all future earnings, if any, to finance business growth and development, and does not anticipate paying any cash dividends in the foreseeable future .

The company explicitly flags several structural headwinds and execution risks. The development of biopharmaceutical product candidates is capital-intensive, and the company will require significant additional funds to continue its research and development, preclinical testing, and future clinical trials . There is no guarantee that this additional funding will be available on acceptable terms or at all, and failure to obtain necessary capital could force delays, reductions, or termination of product development and commercialization efforts . Clinical development is a lengthy, expensive process with uncertain outcomes, and earlier study results may not predict future trial results, leading to potential delays or failures in commercialization . The company's product candidates are in early stages of development and may fail or suffer delays, materially harming their commercial viability . Undesirable side effects from product candidates, such as those observed with Varseta-M, could delay or prevent regulatory approval, limit commercial labeling, or result in negative consequences post-marketing . Delays or difficulties in patient enrollment in clinical trials could also impede regulatory approvals . The company's reliance on third-party manufacturers, many of whom are sole-source suppliers, for clinical and preclinical supplies exposes it to risks of limited or interrupted supply or unsatisfactory quality . The novel technologies underlying the PROBODY platform are unproven and may not result in marketable products, and the market may not be receptive to this new therapeutic modality . Furthermore, the company's collaborations with third parties may not be successful, potentially limiting the capitalization of the PROBODY platform's market potential .

Risk Factors

The company faces material risks including the inherent uncertainty and high failure rate of clinical development for novel biopharmaceutical products, with an accumulated deficit of $711.9 million as of December 31, 2025, and no product sales revenue to date . There is a significant risk of needing substantial additional funds beyond the current capital, which is expected to fund operations only into the second quarter of 2027 , and such funding may not be available on acceptable terms, potentially forcing delays or termination of development programs . Undesirable side effects from product candidates, such as the Grade 5 treatment-related acute kidney injury reported for Varseta-M , could delay or prevent regulatory approval or lead to market withdrawal. Reliance on sole-source third-party manufacturers, including those in Europe and China, exposes the company to supply chain disruptions, increased costs, and geopolitical risks, including potential trade restrictions under acts like the BIOSECURE Act . The novel PROBODY technology is unproven, and its product candidates may not demonstrate therapeutic effectiveness or protection from toxicity in humans, or may trigger immune responses like anti-drug antibodies . Intellectual property risks include the potential for patents not being broad enough, challenges to validity, and the high cost and time-consuming nature of litigation, which could divert resources and impact the ability to commercialize products . Regulatory risks include potential delays or denials of approval by the FDA or foreign authorities due to disagreements on trial design, data interpretation, or manufacturing compliance, and the evolving regulatory framework for AI Technologies could limit their use or increase operating expenses . Healthcare legislative reforms, such as the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act, could lead to unfavorable pricing regulations, reduced reimbursement, and decreased demand for products .

Management Priorities

Management's overall tone emphasizes a focused strategy leveraging the proprietary PROBODY platform to develop conditionally activated biologic therapeutics for unmet needs in oncology, with a clear mission to urgently advance its pipeline. Dr. Sean McCarthy, CEO and Chairman, leads an experienced team dedicated to cancer care. Key strategic priorities include advancing Varseta-M towards late-phase development, with an initial focus on a registrational study in late-line CRC starting in the first half of 2027 , and exploring its potential in earlier lines of therapy through combination studies, with initial data from a Varseta-M and bevacizumab combination study expected by the first half of 2027 . Another priority is to build a multi-program clinical pipeline, exemplified by CX-801, a masked interferon alpha-2b, with Phase 1 clinical data from the CX-801 and KEYTRUDA combination dose escalation expected by the end of 2026 . The company also prioritizes leveraging strategic partnerships to extend technology reach and secure non-dilutive capital, while fostering a patient-focused culture. Management believes existing capital resources will fund operations into the second quarter of 2027 , but acknowledges the need for additional funding.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Varsetatug Masetecan (Varseta-M)
  3. [3] Item 1, Business — Varsetatug Masetecan (Varseta-M)
  4. [4] Item 1, Business — CX-801
  5. [5] Item 1, Business — Preclinical PROBODY Program and Platform
  6. [6] Item 7, MD&A — Revenue
  7. [7] Item 7, MD&A — Revenue
  8. [8] Item 7, MD&A — Revenue
  9. [9] Item 7, MD&A — Research and Development Expenses
  10. [10] Item 7, MD&A — Research and Development Expenses
  11. [11] Item 7, MD&A — Research and Development Expenses
  12. [12] Item 7, MD&A — General and Administrative Expenses
  13. [13] Item 7, MD&A — General and Administrative Expenses
  14. [14] Item 7, MD&A — Liquidity and Capital Resources
  15. [15] Item 7, MD&A — Liquidity and Capital Resources
  16. [16] Item 7, MD&A — Liquidity and Capital Resources
  17. [17] Item 7, MD&A — Liquidity and Capital Resources
  18. [18] Item 7, MD&A — Summary Statement of Cash Flows
  19. [19] Item 7, MD&A — Summary Statement of Cash Flows
  20. [20] Item 7, MD&A — Summary Statement of Cash Flows
  21. [21] Item 7, MD&A — Summary Statement of Cash Flows
  22. [22] Item 7, MD&A — Revenue
  23. [23] Item 7, MD&A — Research and Development Expenses
  24. [24] Item 7, MD&A — Research and Development Expenses
  25. [25] Item 7, MD&A — Restructuring
  26. [26] Item 7, MD&A — Restructuring
  27. [27] Item 7, MD&A — Restructuring
  28. [28] Item 7, MD&A — Restructuring
  29. [29] Item 7, MD&A — Liquidity and Capital Resources
  30. [30] Item 7, MD&A — Liquidity and Capital Resources
  31. [31] Item 7, MD&A — Liquidity and Capital Resources
  32. [32] Item 7, MD&A — Liquidity and Capital Resources
  33. [33] Item 7, MD&A — Liquidity and Capital Resources
  34. [34] Item 7, MD&A — Liquidity and Capital Resources
  35. [35] Item 7, MD&A — Liquidity and Capital Resources
  36. [36] Item 7, MD&A — Liquidity and Capital Resources
  37. [37] Item 7, MD&A — Varsetatug Masetecan March 2026 Interim Data Update from Phase 1 Dose Expansions
  38. [38] Item 7, MD&A — Varsetatug Masetecan March 2026 Interim Data Update from Phase 1 Dose Expansions
  39. [39] Item 7, MD&A — Varsetatug Masetecan March 2026 Interim Data Update from Phase 1 Dose Expansions
  40. [40] Item 7, MD&A — Varsetatug Masetecan March 2026 Interim Data Update from Phase 1 Dose Expansions
  41. [41] Item 7, MD&A — CX-801 Development
  42. [42] Item 7, MD&A — CX-801
  43. [43] Item 7, MD&A — Research and Development Expenses
  44. [44] Item 7, MD&A — Restructuring
  45. [45] Item 7, MD&A — Restructuring
  46. [46] Item 1, Business — Manufacturing
  47. [47] Item 1A, Risk Factors — We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates.
  48. [48] Item 7, MD&A — Liquidity and Capital Resources
  49. [49] Item 1A, Risk Factors — The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital.
  50. [50] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities — Dividend Policy
  51. [51] Item 1A, Risk Factors — We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates.
  52. [52] Item 1A, Risk Factors — We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates.
  53. [53] Item 1A, Risk Factors — Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
  54. [54] Item 1A, Risk Factors — Our product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.
  55. [55] Item 1A, Risk Factors — Our product candidates, including Varseta-M and CX-801, may cause undesirable side effects at any time during or after the clinical trial process that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including withdrawal from the market.
  56. [56] Item 1A, Risk Factors — If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
  57. [57] Item 1A, Risk Factors — Because we have no long-term contracts with and rely on third-party manufacturing and supply partners, most of which are sole source suppliers, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.
  58. [58] Item 1A, Risk Factors — Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products.
  59. [59] Item 1A, Risk Factors — We have entered, and may in the future seek to enter, into collaborations with third parties for the development and commercialization of our product candidates using our PROBODY platform. If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our PROBODY platform and resulting product candidates.
  60. [60] Item 1A, Risk Factors — We are a clinical-stage biopharmaceutical company with a limited operating history and have not generated any revenue from product sales. We have a history of losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock.
  61. [61] Item 1A, Risk Factors — We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates.
  62. [62] Item 7, MD&A — Varsetatug Masetecan March 2026 Interim Data Update from Phase 1 Dose Expansions
  63. [63] Item 1A, Risk Factors — We will continue to conduct clinical trials and contract with third-party manufacturers in foreign countries, including Europe and China, which could expose us to risks that could have a material adverse effect on the success of our business.
  64. [64] Item 1A, Risk Factors — Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products.
  65. [65] Item 1A, Risk Factors — Risks Related to Intellectual Property
  66. [66] Item 1A, Risk Factors — We may be unable to obtain or be delayed in obtaining U.S. or foreign regulatory approval and, as a result, be unable or delayed in being able to commercialize our product candidates.
  67. [67] Item 1A, Risk Factors — Healthcare legislative reform measures may have a material and adverse effect on our business and results of operations.
  68. [68] Item 1, Business — Our Corporate Strategy

Analysis on 5/22/2026